Stay updated on Nivolumab Combo in Relapsed/Refractory HL Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Combo in Relapsed/Refractory HL Clinical Trial page.

Latest updates to the Nivolumab Combo in Relapsed/Refractory HL Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedFooter updated to Revision: v3.4.2; the funding-lapse notice and the older Revision: v3.4.1 text were removed.SummaryDifference0.3%

- Check23 days agoChange DetectedAdded a system-wide notice about potential data delays due to a lapse in government funding and updated operating status guidance, with references to cc.nih.gov and opm.gov. Updated the page revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.3%

- Check30 days agoChange DetectedAdded a glossary display and updated QC-related metadata to show 2025-10-20 Last Update Submitted that Met QC Criteria and Last Update Posted, along with No FEAR Act Data and Revision: v3.4.0. Removed older QC metadata (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data) and the prior Revision: v3.3.4.SummaryDifference0.3%

- Check44 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. No substantive changes to study content, layout, or links are evident.SummaryDifference0.0%

- Check65 days agoChange DetectedA consolidated Locations section was added and organized to list study sites in California, Connecticut, Texas, and Washington, with related per-location entries updated accordingly.SummaryDifference0.4%

- Check94 days agoChange DetectedPublications section wording now states that publications are automatically filled from PubMed, and the revision label was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Nivolumab Combo in Relapsed/Refractory HL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Combo in Relapsed/Refractory HL Clinical Trial page.